Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

• Forschungsstelle: INNOSUISSE
• Projektnummer: 13265.1 PFLS-LS
• Projekttitel Englisch: Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Kurzbeschreibung (Deutsch)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Kurzbeschreibung (Englisch)

Hemoglobin targeted therapeutics - early stage development of a novel class of plasma protein products to control hemolysis mediated adverse effects

Abstract (Deutsch)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.

Abstract (Englisch)

Red blood cell destruction results in direct contact of released free hemoglobin with susceptible tissues.|Ensuing adverse effects include renal damage, hemodynamic instability and inflammation in patients|receiving massive blood transfusion or extracorporeal cardio-pulmonary support or with hemolytic anemia.|In this project novel plasma derived bio-therapeutics will be developed that will for the first time allow for|targeted prevention of hemoglobin-driven adverse outcomes with the goal of increasing safety of blood|transfusion and critical care.